Ravicti Receives Regulatory Approval in Saudi Arabia, Qatar, and Kuwait for Urea Cycle Disorders
Key Insights
Immedica (search) announced that Ravicti (glycerol phenylbutyrate) has received regulatory approval in Saudi Arabia, Qatar, and Kuwait for treating urea cycle disorders (search).
The approval expands access to this rare disease treatment across the MENA region, addressing a significant unmet medical need for patients with metabolic disorders.
Urea cycle disorders (search) affect 1 in 35,000 newborns and can cause life-threatening hyperammonemic crises (search) leading to brain damage, coma, or death.
Immedica (search) announced on August 18, 2025, that Ravicti (glycerol phenylbutyrate) has received regulatory approval in Saudi Arabia, Qatar, and Kuwait for the treatment of urea cycle disorders (search) (UCDs). This milestone represents a significant expansion of access to rare disease treatments across the Middle East and North Africa (MENA) region.
"We are pleased to expand the availability of Ravicti to patients in these three regions," said Anders Edvell, CEO of Immedica (search). "This approval underscores our commitment to advancing rare disease care and ensuring that patients have access to the treatments they need."
Clinical Significance for Urea Cycle Disorders
Urea cycle disorders (search) represent a group of metabolic diseases that affect specific enzymes or transporters in the urea cycle, leading to elevated ammonia or glutamine levels in the circulation. These disorders occur in 1 in 35,000 newborns, making them a rare but serious medical condition requiring specialized treatment.
The clinical presentation of UCDs can vary significantly, with more severe defects typically manifesting early in life. Patients may experience hyperammonemic crises (search), episodes where ammonia levels in the blood become excessively high, potentially resulting in irreversible brain damage, coma, or death. Beyond these acute episodes, patients often present with more subtle symptoms including vomiting, refusal to feed, irritability, muscular hypotonia, and delayed motor and psychointellectual development.
Treatment Indication and Mechanism
Ravicti is indicated for patients of all ages with UCDs, including deficiencies of carbamoyl phosphate synthetase I (search) (CPS), ornithine carbamoyltransferase (search) (OTC), argininosuccinate synthetase (search) (ASS), argininosuccinate lyase (search) (ASL), arginase I (search) (ARG), and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH). The medication is specifically prescribed for patients who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
The medicine functions by reducing ammonia levels in the blood to minimize the risk of neurological consequences. Treatment with Ravicti must be combined with dietary protein restriction and, in some cases, dietary supplements such as essential amino acids, arginine, citrulline, and protein-free calorie supplements.
Regional Impact and Company Background
Ashraf Attia, General Manager MENA at Immedica (search), emphasized the regional significance of this approval: "This approval is a significant step forward in our mission to provide treatments for rare diseases in the MENA region. We are grateful for the support of the health authorities and look forward to continuing our work to improve patient outcomes."
Immedica (search), headquartered in Stockholm, Sweden, specializes in the commercialization of medicines for rare diseases and specialty care products. The company operates across multiple therapeutic areas including rare metabolic, rare hematology and oncology, rare neurology, and specialty care. Founded in 2018, Immedica currently employs approximately 130 people across Europe, the Middle East, and the United States, serving patients in more than 50 countries through its global distribution network.